Source:http://linkedlifedata.com/resource/pubmed/id/12815476
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2003-6-19
|
| pubmed:abstractText |
We describe the course of 25 patients with myelofibrosis (MF) due to agnogenic myeloid metaplasia (n=19) or essential thrombocytosis (n=6) who underwent allogeneic stem cell transplantation (SCT) at one of two Canadian centers. The median age at transplantation was 48.7 (IQR 45.9-50.4) years and transplantation was carried out at a median of 10.7 (IQR 5.67-26.5) months after diagnosis. Granulocyte engraftment (absolute neutrophil count >0.5 x 109/l) occurred at a median of 20 days after transplantation for splenectomized patients, compared with 27.5 days for nonsplenectomized individuals (P=0.03). Increased risk of grade II-IV acute graft-versus-host disease (P=0.04) was noted in patients transplanted after splenectomy. Patients with MF received 0.264+/-0.189 U of packed red blood cells per day over the first 180 days after transplantation, and remained dependent on red blood cell transfusions for a median of 123 (IQR 48-205) days. Complete remission of MF was documented in 33% of evaluable patients. The 1 year cumulative nonrelapse mortality was 48.3%. Median survival for this group of patients was 393 (IQR 109-1014+) days, with a projected 2-year overall survival of 41%. We conclude that allogeneic SCT offers a reasonable chance for prolonged survival in patients with advanced MF, but this occurs at the cost of considerable toxicity and nonrelapse mortality.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0268-3369
|
| pubmed:author |
pubmed-author:DalyAA,
pubmed-author:ForrestDD,
pubmed-author:HasegawaWW,
pubmed-author:HoggeDD,
pubmed-author:KissTT,
pubmed-author:LavoieJJ,
pubmed-author:LiptonJJ,
pubmed-author:MessnerHH,
pubmed-author:NantelSS,
pubmed-author:NevillTT,
pubmed-author:ShepherdJJ,
pubmed-author:SongKK,
pubmed-author:SutherlandHH,
pubmed-author:TozeCC
|
| pubmed:issnType |
Print
|
| pubmed:volume |
32
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
35-40
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:12815476-Erythrocyte Transfusion,
pubmed-meshheading:12815476-Female,
pubmed-meshheading:12815476-Follow-Up Studies,
pubmed-meshheading:12815476-Graft Survival,
pubmed-meshheading:12815476-Graft vs Host Disease,
pubmed-meshheading:12815476-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:12815476-Hepatic Veno-Occlusive Disease,
pubmed-meshheading:12815476-Humans,
pubmed-meshheading:12815476-Male,
pubmed-meshheading:12815476-Middle Aged,
pubmed-meshheading:12815476-Primary Myelofibrosis,
pubmed-meshheading:12815476-Splenectomy,
pubmed-meshheading:12815476-Survival Analysis,
pubmed-meshheading:12815476-Thrombocytosis,
pubmed-meshheading:12815476-Transplantation, Homologous
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Stem cell transplantation for myelofibrosis: a report from two Canadian centers.
|
| pubmed:affiliation |
Allogeneic Bone Marrow Transplant Program, Princess Margaret Hospital, University Health Network, Toronto, Ont., Canada.
|
| pubmed:publicationType |
Journal Article
|